Jazz’s Vyxeos (daunorubicin and cytarabine liposome) for Injection Receives Health Canada Approval for the Treatment of High-risk Acute Myeloid Leukemia

July 9, 2021 Auto Bot regulatory 0

Shots:

  • The approval is based on the results from a P-III study that involves assessing Vyxeos (IV infusion) vs a current conventional treatment group in 309 adult patients aged 60-75 yrs. with newly diagnosed t-AML or AML-MRC
  • The study met its 1EPs i.e the therapy demonstrates the improvement in OS; m-OS (9.6 vs 6.0 mos.)
  • Vyxeos (daunorubicin & cytarabine liposome) is a 1st CT treatment option for adults with newly diagnosed t-AML or AML with AML-MRC while the therapy has developed with the company’s CombiPlex platform to facilitate the design & rapid evaluation of various combinations of therapies

Click here to read full press release/ article | Ref: Jazz Pharmaceuticals | Image: Jazz Pharmaceuticals

The post Jazz’s Vyxeos (daunorubicin and cytarabine liposome) for Injection Receives Health Canada Approval for the Treatment of High-risk Acute Myeloid Leukemia first appeared on PharmaShots.